Merit Financial Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-2,478
Closed -$229K 265
2021
Q2
$229K Buy
2,478
+58
+2% +$4.93K 0.02% 241
2021
Q1
$215K Buy
+2,420
New +$240K 0.02% 221
2020
Q2
Sell
-14,538
Closed -$455K 219
2020
Q1
$455K Buy
+14,538
New +$486K 0.05% 131

Other funds holding ARKG

Merit Financial Group's ARKG Position: Q3 2021 in Review

Merit Financial Group sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 2,478 shares — an estimated $229K sold.

Merit Financial Group first reported a position in ARKG in Q1 2020 and held it in 3 quarters. The position peaked at $455K in Q1 2020. 468 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

  • Merit Financial Group reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
  • Merit Financial Group sold 2,478 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $229K.
  • Merit Financial Group first reported a position in ARK Genomic Revolution ETF in Q1 2020 and held it in 3 quarters.
  • Merit Financial Group's ARK Genomic Revolution ETF position peaked at $455K in Q1 2020.
  • 468 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on Merit Financial Group's 13F filing for Q3 2021, filed 27 Oct 2021.